Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action antagonists, enhancers |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 1 | China | 01 Nov 2024 | |
Solid tumor | Phase 1 | China | 01 Nov 2024 | |
Neoplasms | Preclinical | China | 29 Apr 2025 |